Antonescu C R, Argani P, Erlandson R A, Healey J H, Ladanyi M, Huvos A G
Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Cancer. 1998 Oct 15;83(8):1504-21. doi: 10.1002/(sici)1097-0142(19981015)83:8<1504::aid-cncr5>3.0.co;2-b.
Skeletal myxoid chondrosarcoma (SMC) is considered to be either a typical chondrosarcoma with prominent myxoid alterations or an altogether unique malignant cartilage tumor. Extraskeletal myxoid chondrosarcoma (EMC) is a relatively rare but well-recognized neoplasm. It was initially thought to be a low grade sarcoma of cartilage derivation and was recently found, in most cases, to contain a reciprocal t(9;22), resulting in a fusion of the EWS and CHN genes. Are SMC and EMC the same entity arising in two different locations, or are they two separate entities? To the authors' knowledge, this study represents the first systematic attempt to answer this question.
Forty consecutive cases of EMC (20 cases) and SMC (20 cases) were compared by light and electron microscopy, immunohistochemistry, and molecular analysis. The mean clinical follow-up for both groups was 55 months. Histologic criteria for SMC consisted of 95% myxoid matrix, with only minimal hyaline cartilage formation.
The gender distribution was identical in both groups (13 males and 7 females). The mean age was 55 years for EMC patients and 45 years for SMC patients. The EMC tumors were predominantly located in the deep soft tissues of the lower extremity (60%) and buttock (20%), and the mean tumor size was 13 cm. SMC was most commonly located in the bones around the hip joint (pelvis 35%; proximal femur 20%) and shoulder (20%); the mean size was 9 cm. Histologic grade in the EMC group correlated with survival (82% of the high grade tumors metastasized). Electron microscopy performed in 8 EMC cases revealed intracisternal microtubules in 3 cases and prominent mitochondria in 5, whereas in 5 SMC cases it revealed only inconspicuous organelles. Molecular analysis for the EWS-CHN fusion RNA resulting from the t(9;22) was performed in 15 cases (9 EMC and 6 SMC) and was detected in 7 of 9 EMC cases and 0 of 6 SMC cases. In one case, the molecular structure of the EWS-CHN fusion RNA was novel. The probability of metastasis was significantly higher (P=0.004) for the EMC group than for the SMC group.
Although similar light microscopic features are noted in EMC and SMC, fundamental differences are noted at the ultrastructural and molecular levels, suggesting that EMC and SMC represent two distinct entities in the chondrosarcoma family of tumors.
骨黏液样软骨肉瘤(SMC)被认为是一种具有显著黏液样改变的典型软骨肉瘤,或是一种完全独特的恶性软骨肿瘤。骨外黏液样软骨肉瘤(EMC)是一种相对罕见但已被充分认识的肿瘤。它最初被认为是一种起源于软骨的低级别肉瘤,最近发现,在大多数病例中,它含有一种相互易位t(9;22),导致EWS和CHN基因融合。SMC和EMC是起源于两个不同部位的同一实体,还是两个不同的实体?据作者所知,本研究是回答这个问题的首次系统性尝试。
通过光镜和电镜、免疫组织化学及分子分析,对40例连续的EMC(20例)和SMC(20例)病例进行比较。两组的平均临床随访时间均为55个月。SMC的组织学标准为黏液样基质占95%,仅有极少的透明软骨形成。
两组的性别分布相同(男性13例,女性7例)。EMC患者的平均年龄为55岁,SMC患者为45岁。EMC肿瘤主要位于下肢深部软组织(60%)和臀部(20%),平均肿瘤大小为13 cm。SMC最常见于髋关节周围的骨骼(骨盆35%;股骨近端20%)和肩部(20%);平均大小为9 cm。EMC组的组织学分级与生存率相关(82%的高级别肿瘤发生转移)。对8例EMC病例进行的电镜检查显示,3例有核内微管,5例有显著的线粒体,而5例SMC病例仅显示不明显的细胞器。对15例病例(9例EMC和6例SMC)进行了t(9;22)导致的EWS-CHN融合RNA的分子分析,9例EMC病例中有7例检测到,6例SMC病例中均未检测到。在1例病例中,EWS-CHN融合RNA的分子结构是新的。EMC组的转移概率显著高于SMC组(P = 0.004)。
尽管EMC和SMC在光镜下有相似特征,但在超微结构和分子水平上存在根本差异,提示EMC和SMC代表软骨肉瘤肿瘤家族中的两个不同实体。